To include your compound in the COVID-19 Resource Center, submit it here.

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerges from stealth with a clinical psoriasis program from Swedish biotech Affibody

Inmagene emerged from stealth with a clinical psoriasis program from Swedish biotech Affibody.

Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program it in-licensed from Swedish biotech Affibody. The candidate, IMG-020, is expected to be cheaper to manufacture and more convenient to administer than marketed antibodies against the same target.

According to Inmagene, biologics account for only 17% of pharmaceutical sales for autoimmune diseases in China compared with 80%

Read the full 816 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE